A phase II trial of a multi‐agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1545-5017|61|4|636-642

ISSN： 1545-5009

Source： PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol.61, Iss.4, 2014-04, pp. : 636-642

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Combined Biodifferentiating and Antiangiogenic Oral Metronomic Therapy is Feasible and Effective in Relapsed Solid Tumors in Children: Single-Center Pilot Study

By  

Oncology Research and Treatment, Vol. 29, Iss. 7, 2006-07 ,pp. : 308-313

Karger

Access to resources Recommend Favorite

Metronomic Antiangiogenic Therapy with Capecitabine and Celecoxib in Advanced Tumor Patients – Results of a Phase II Study

By  

Oncology Research and Treatment, Vol. 30, Iss. 12, 2007-11 ,pp. : 629-635

Karger

Access to resources Recommend Favorite

Phase II Study of an ‘All-Oral’ Regimen of Capecitabine, Idarubicin and Cyclophosphamide for Metastatic Breast Cancer – Safety, Efficacy and Quality of Life

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 520-525

Karger

Access to resources Recommend Favorite

Bevacizumab plus Low-Dose Metronomic Oral Cyclophosphamide in Heavily Pretreated Patients with Recurrent Ovarian Cancer

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 98-104

Karger

Access to resources Recommend Favorite

An Alternating Regimen of Irinotecan/ 5-Fluorouracil/Folinic Acid and Oxaliplatin/ 5-Fluorouracil/Folinic Acid in Metastatic Colorectal Cancer: A Phase II Trial

By  

Oncology, Vol. 69, Iss. 4, 2005-12 ,pp. : 283-289

Karger

Access to resources Recommend Favorite